Resultats de la cerca - Jan Steffel
- Mostrar 1 - 20 resultats de 48
- Anar a la pàgina següent
-
1
-
2
Superresponse to Cardiac Resynchronization Therapy per Jan Steffel, Frank Ruschitzka
Publicat 2014Artigo -
3
Sweet and Sour per Thomas F. Lüscher, Jan Steffel
Publicat 2008Carta -
4
Tissue Factor in Cardiovascular Diseases per Jan Steffel, Thomas F. Lüscher, Felix C. Tanner
Publicat 2006Revisão -
5
-
6
-
7
-
8
Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy per S. Schmidt, David Hürlimann, Christoph Starck, G Hindricks, Thomas F. Lüscher, Frank Ruschitzka, Jan Steffel
Publicat 2013Artigo -
9
-
10
The COMPASS Trial per Jan Steffel, John W. Eikelboom, Sonia S. Anand, Olga Shestakovska, Salim Yusuf, Keith A.A. Fox
Publicat 2020Artigo -
11
-
12
-
13
-
14
The effects of continuous positive airway pressure therapy withdrawal on cardiac repolarization: data from a randomized controlled trial per Valentina A. Rossi, Anne‐Christin Stoewhas, Giovanni Camen, Jan Steffel, Konrad E. Bloch, John Stradling, Marianne Køhler
Publicat 2012Artigo -
15
Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling per Georg Fröhlich, Jan Steffel, David Hürlimann, Frank Enseleit, Thomas F. Lüscher, Frank Ruschitzka, William T. Abraham, Johannes Holzmeister
Publicat 2010Artigo -
16
Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents per Giovanni G. Camici, Jan Steffel, I. Amanovic, Alexander Breitenstein, Jeannette Baldinger, Stephan Sylvest Keller, Thomas F. Lüscher, Felix C. Tanner
Publicat 2009Artigo -
17
Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systemati... per Neal A. Chatterjee, Attila Róka, Steven A. Lubitz, Michael R. Gold, Claude Daubert, Cecilia Linde, Jan Steffel, G. André Ng, Theofanie Mela
Publicat 2015Revisão -
18
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial per Jan Steffel, Robert P. Giugliano, Eugene Braunwald, Sabina A. Murphy, Dan Atar, Hein Heidbüchel, A. John Camm, Elliott M. Antman, Christian T. Ruff
Publicat 2015Artigo -
19
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation per Jan Steffel, Christian T. Ruff, Ophelia Yin, Eugene Braunwald, Jeong‐Gun Park, Sabina A. Murphy, Stuart J. Connolly, Elliott M. Antman, Robert P. Giugliano
Publicat 2021Artigo -
20
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling per Jan Steffel, Robert P. Giugliano, Eugene Braunwald, Sabina A. Murphy, Michele Mercuri, Youngsook Choi, Philip E. Aylward, Harvey D. White, Josè Luis Zamorano, Elliott M. Antman, Christian T. Ruff
Publicat 2016Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Cardiology
Atrial fibrillation
Warfarin
Intensive care medicine
Engineering
Mechanical engineering
Stroke (engine)
Heart failure
Cardiac resynchronization therapy
Confidence interval
Ejection fraction
Myocardial infarction
Surgery
Vitamin K antagonist
Biology
Randomized controlled trial
Anesthesia
Coagulation
Disease
Edoxaban
Endocrinology
Hazard ratio
Heart Rhythm
Receptor
Rivaroxaban
Tissue factor
Cell biology
Dabigatran